Verified factor-similar pair

FDMO vs MMTM

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

UMD
Similarity score
81
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • MMTM has the lower published fee (0.12% vs 0.15%).
  • FDMO is cheaper on dividend valuation (163 vs 174, where 100 is each fund's historical median).
  • FDMO has the stronger regression fit (adjusted R-squared 0.964 vs 0.949).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

FDMO

Fidelity Momentum Factor ETF
UMD
Adj. R2
0.964
Rel. Sharpe
1.058
Mkt beta
1.04
AUM
US$785M
MER
0.15%
Valuation
163

MMTM

State Street SPDR S&P 1500 Momentum Tilt ETF
UMD
Adj. R2
0.949
Rel. Sharpe
1.053
Mkt beta
1.00
AUM
US$161M
MER
0.12%
Valuation
174

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
FDMO
-0.03
|t|
-0.7
MMTM
-0.11
|t|
-3.3
diff +0.08
HML
FDMO
-0.05
|t|
-1.6
MMTM
+0.02
|t|
+0.6
diff -0.07
RMW
FDMO
-0.09
|t|
-2.2
MMTM
+0.06
|t|
+1.6
diff -0.15
CMA
FDMO
-0.02
|t|
-0.4
MMTM
-0.02
|t|
-0.4
diff +0.00
UMD
FDMO
+0.25
|t|
+9.7
MMTM
+0.14
|t|
+6.2
diff +0.10

Why This Pair Matches

Exposure level
80
Exposure shape
82
Mkt beta diff
0.04
Rel. Sharpe diff
0.005

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

FDMO fund page MMTM fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.